Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002333 · ClinicalTrials.gov registry record · Phase 2
A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 900
- Enrollment target
NCT00002333: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT00002333 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 900 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (577% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002333, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 900 participants
- Enrollment target
Study Summary
To compare the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone, zalcitabine (dideoxycytidine; ddC) alone, and both in combination, in patients discontinuing or unable to take zidovudine (AZT).
Interventions
- DRUG Saquinavir
- DRUG Zalcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Phase | Phase 2 |
What the finished NCT00002333 record still lists
NCT00002333 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (577% higher).
The record links to 0 conditions, and to 2 interventions - of which Saquinavir is the first listed.
NCT00002333 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002333 about?
NCT00002333 is a clinical study titled "A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine". To compare the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone, zalcitabine (dideoxycytidine; ddC) alone, and both in combination, in patients discontinuing or unable to take zidovudine (AZT).
What is the current status of trial NCT00002333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 900 participants.
What interventions are being tested in trial NCT00002333?
The interventions under investigation include: Saquinavir (DRUG), Zalcitabine (DRUG).
Who is sponsoring clinical trial NCT00002333?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002333's enrollment target sits among peer trials
900 30th of 2000 higher than 1,968 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study